Sanofi to acquire Kadmon for $1.9B

Listen
Text
  • Small
  • Medium
  • Large

Sanofi said Sept. 8 that it will acquire New York City-based drugmaker Kadmon for $1.9 billion. 

Under the deal, which has already been approved unanimously by both companies' boards, Sanofi will gain Kadmon's drug Rezurock, which was approved in July to treat chronic graft-versus-host disease in both adults and adolescents. 

Kadmon focuses on developing drugs for diseases with significant unmet medical needs. 

"By leveraging Sanofi's global resources and long-standing expertise in developing and commercializing innovative medicines, Rezurock is now well positioned for global accessibility, faster," Harlan Waksal, MD, Kadmon's president and CEO said in a news release. 

Sanofi said it expects the deal to close in the fourth quarter of this year. 

Read the full news release here

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars